Crinetics Pharmaceuticals, Inc.
CRNX
$29.24
$1.023.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 14.53% | 7.53% | |||
| Gross Profit | -13.99% | -7.53% | |||
| SG&A Expenses | 26.07% | 8.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.97% | 7.91% | |||
| Operating Income | -17.58% | -7.91% | |||
| Income Before Tax | -20.07% | -4.90% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -20.07% | -4.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.07% | -4.90% | |||
| EBIT | -17.58% | -7.91% | |||
| EBITDA | -17.59% | -7.96% | |||
| EPS Basic | -17.99% | 8.17% | |||
| Normalized Basic EPS | -18.02% | 8.17% | |||
| EPS Diluted | -18.06% | 8.17% | |||
| Normalized Diluted EPS | -18.02% | 8.17% | |||
| Average Basic Shares Outstanding | 1.76% | 14.24% | |||
| Average Diluted Shares Outstanding | 1.76% | 14.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||